IP Library Patent Application 17151410
Patent Application
App. No. 17/151,410

Device And Method For Diffusing High Concentration NO With Inhalation Therapy Gas

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/151,410
Abstract

Systems and methods of the present invention can enable high concentration NO to be delivered into ventilator breathing circuits, via a diffusing device, without generating undesirably large amounts of NO 2 .

Claims (30)

1 . A method of delivery nitric oxide (NO) to a patient, the method comprising:

combining a first gas stream comprising molecular oxygen (O 2 ) and a second gas stream comprising NO to provide a combined gas stream; and

delivering the combined gas stream to the patient,

wherein the diffusing of NO and O 2 in the combined gas stream occurs sufficiently rapidly that less than 1 ppm of NO 2 is delivered to the patient.

2 . The method of claim 1 , wherein the second gas stream is provided by an NO source having an NO concentration of greater than 800 ppm to about 10,000 ppm.

3 . The method of claim 1 , wherein the combined gas stream has an NO concentration of about 1 ppm to about 80 ppm.

4 . The method of claim 1 , wherein the first gas is a breathable gas comprising molecular N 2 and molecular O 2 , and the second gas comprises molecular NO and molecular N 2 .

5 . The method of claim 1 , wherein the second gas stream initially enters the first gas stream at an angle in the range of about 60° to about 120°.

6 . The method of claim 1 , wherein the volumetric flow rate of the second gas is linearly proportional to the volumetric flow rate of the first gas.

7 . The method of claim 1 , wherein the first gas stream has a first velocity and the second gas stream has a second velocity, and the ratio of the first velocity to the second velocity is less than 2:1.

8 . The method of claim 7 , wherein the ratio of the first velocity to the second velocity is less than or equal to about 1:1.

9 . The method of claim 8 , wherein the ratio of less than or equal to about 1:1 is provided when the first gas stream has a volumetric flow rate of less than 2 SLPM.

10 . The method of claim 1 , wherein the second gas stream enters the first gas stream at or near the central midpoint of the highest velocity of the first gas stream.

11 . The method of claim 1 , wherein the second gas stream is injected into the first gas stream as a plurality of pulses.

12 . The method of claim 1 , wherein the device comprises:

a body comprising a wall having a thickness, an outer surface, and an inner surface surrounding a hollow internal region;

a projection extending from the inner surface of the body and into the hollow internal region; and

an injection channel passing through the wall and projection to an injection port such that the injection port injects the high concentration gas into the transverse gas stream at a distance from the inner surface of the body.

13 . The method of claim 12 , wherein the hollow internal region has a diameter, and a length of the projection from the inner surface to the injection port outlet is in the range of about 30% to about 45% of the diameter of the hollow internal region.

14 . The method of claim 12 , wherein the device comprises a plurality of injection ports.

15 . The method of claim 1 , wherein the device is integral to an injector module comprising a flow sensor.

16 . A method of delivery nitric oxide (NO) to a patient, the method comprising:

receiving a dose of NO from a user;

combining a first gas stream comprising molecular oxygen (O 2 ) and a second gas stream comprising NO to provide a combined gas stream; and

delivering the combined gas stream to the patient,

wherein the diffusing of NO and O 2 in the combined gas stream occurs sufficiently rapidly that less than 1 ppm of NO 2 is delivered to the patient.

17 . The method of claim 16 , the combined gas stream provides the dose of NO at a concentration of about 1 ppm to about 80 ppm.

18 . The method of claim 16 , wherein the volumetric flow rate of the second gas is linearly proportional to the volumetric flow rate of the first gas.

19 . The method of claim 16 , wherein the first gas stream has a first velocity and the second gas stream has a second velocity, and the ratio of the first velocity to the second velocity is less than 2:1.

20 . The method of claim 1 , wherein the second gas stream enters the first gas stream at or near the central midpoint of the highest velocity of the first gas stream.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2026
From: FALLIGANT, JOHN C.; TOLMIE, CRAIG R.
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 075520/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 075520/0385 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →